{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T16:40:10Z","timestamp":1750005610448,"version":"3.41.0"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n            <jats:title>Abstract:<\/jats:title>\n            <jats:p>We present the efficacy and safety of 12 weeks of therapy with a fixed dose of ledipasvir\/sofosbuvir in 2 teenagers with HIV\/hepatitis C virus coinfection. Patient 1 presented with compensated cirrhosis, whereas patient 2 had evidence of previous hepatitis B virus infection. Both patients achieved a sustained virologic response 12 weeks after the end of treatment. No serious adverse effects were reported.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000003264","type":"journal-article","created":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T18:31:33Z","timestamp":1625682693000},"page":"1087-1089","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Effective Treatment of Chronic Hepatitis C Virus Infection With Ledipasvir\/Sofosbuvir in 2 Teenagers With HIV Coinfection: A Brief Report"],"prefix":"10.1097","volume":"40","author":[{"given":"Maria","family":"Pokorska-\u015apiewak","sequence":"first","affiliation":[{"name":"Department of Children\u2019s Infectious Diseases, Medical University of Warsaw"},{"name":"Department of Pediatric Infectious Diseases, Regional Hospital of Infectious Diseases, Warsaw, Poland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Dobrzeniecka","sequence":"additional","affiliation":[{"name":"Department of Pediatric Infectious Diseases, Regional Hospital of Infectious Diseases, Warsaw, Poland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"O\u0142dakowska","sequence":"additional","affiliation":[{"name":"Department of Children\u2019s Infectious Diseases, Medical University of Warsaw"},{"name":"Department of Pediatric Infectious Diseases, Regional Hospital of Infectious Diseases, Warsaw, Poland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Marczy\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Children\u2019s Infectious Diseases, Medical University of Warsaw"},{"name":"Department of Pediatric Infectious Diseases, Regional Hospital of Infectious Diseases, Warsaw, Poland."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,7,6]]},"reference":[{"key":"R1-20250615","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/hep.28995","article-title":"The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection.","volume":"66","author":"Balistreri","year":"2017","journal-title":"Hepatology"},{"key":"R2-20250615","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1002\/hep.30123","article-title":"Safety and efficacy of ledipasvir-sofosbuvir with or without ribavirin for chronic hepatitis C in children ages 6-11.","volume":"68","author":"Murray","year":"2018","journal-title":"Hepatology"},{"key":"R3-20250615","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1111\/apt.16037","article-title":"Systematic review with meta-analysis: the efficacy and safety of direct-acting antivirals in children and adolescents with chronic hepatitis C virus infection.","volume":"52","author":"Indolfi","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"R4-20250615","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/MPG.0000000000001872","article-title":"Treatment of chronic hepatitis C virus infection in children: a position paper by the hepatology committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition.","volume":"66","author":"Indolfi","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R5-20250615","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/MPG.0000000000000895","article-title":"Hepatitis C in children co-infected with human immunodeficiency virus.","volume":"61","author":"Indolfi","year":"2015","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R6-20250615","doi-asserted-by":"crossref","first-page":"12309","DOI":"10.1038\/s41598-017-11489-2","article-title":"Prevalence and predictors of liver disease in HIV-infected children and adolescents.","volume":"7","author":"Pokorska-\u015apiewak","year":"2017","journal-title":"Sci Rep"},{"key":"R7-20250615","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/QAD.0000000000001285","article-title":"Coinfection with HIV and hepatitis C virus in 229 children and young adults living in Europe.","volume":"31","year":"2017","journal-title":"AIDS"},{"key":"R8-20250615","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/jvh.13206","article-title":"Longitudinal evolution of vertically HIV\/HCV-co-infected vs HCV-mono-infected children.","volume":"27","author":"Sainz","year":"2020","journal-title":"J Viral Hepat"},{"key":"R9-20250615","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/hep.30840","article-title":"Pharmacokinetics, safety, and efficacy of glecaprevir\/pibrentasvir in adolescents with chronic hepatitis C virus: part 1 of the DORA Study.","volume":"71","author":"Jonas","year":"2020","journal-title":"Hepatology"},{"key":"R10-20250615","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/bcp.13450","article-title":"Ledipasvir and tenofovir drug interaction in human immunodeficiency virus-hepatitis C virus coinfected patients: Impact on tenofovir trough concentrations and renal safety.","volume":"84","author":"Solas","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"R11-20250615","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jpeds.2019.12.034","article-title":"Safety and efficacy of 8 weeks ledipasvir\/sofosbuvir for chronic hepatitis C genotype 4 in children aged 4-10 years.","volume":"219","author":"Behairy","year":"2020","journal-title":"J Pediatr"},{"key":"R12-20250615","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1080\/14787210.2020.1782189","article-title":"Low risk of HBV reactivation in a large European cohort of HCV\/HBV coinfected patients treated with DAA.","volume":"18","author":"Jaroszewicz","year":"2020","journal-title":"Expert Rev Anti Infect Ther"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003264","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T16:05:13Z","timestamp":1750003513000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,6]]},"references-count":12,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000003264","relation":{},"ISSN":["0891-3668"],"issn-type":[{"type":"print","value":"0891-3668"}],"subject":[],"published":{"date-parts":[[2021,7,6]]}}}